Geriatric-oncological Study on Quality of Life and Independence After Radiotherapy

Cancer Clinical Trial

— GOLD-I  

Official title:

Geriatrisch-Onkologische Studie Zur Lebensqualität Und Selbstständigkeit Nach Radiotherapie Geriatric-oncological Study on Quality of Life and Independence After Radiotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05187845
• Other study ID #: RadOnk_2021_GOLD-I
• Status: Completed
• Start date: February 1, 2021
• Est. completion date: April 1, 2022

Study information

• Verified date: November 2022
• Source: University Hospital Heidelberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Elderly patients * with multiple comorbidities are underrepresented in most radio-oncology studies. In times of individualized therapy and when weighing up oncological over- or under-therapy, this observational study is a step towards the implementation of established geriatric instruments and concepts in radiation oncology. As part of the initial outpatient consultation on radiotherapy, the quality of life of patients older than 70 years before the start of therapy is assessed using the EORTC QLQ-C30 and ELD14 questionnaires. Furthermore, a geriatric screening is carried out using the G8 questionnaire. The geriatric screening carried out in routine clinical practice with little effort is used to filter out patients with no risk of increased vulnerability - these participants do not require any further examinations.

Description:

Vulnerable patients with deficits (G8 score <15 pts) receive a geriatric assessment (Comprehensive geriatric assessment (CGA)) consisting of abbreviated comprehensive geriatric assessment (aCGA), appetite (Mini Nutritional Assessment (short form = MNA-SF)) at the beginning and end of radiotherapy ), physical functionality (Short physical performance battery) and measurement of hand strength. In addition, these patients receive an individualized inpatient geriatric-oncological complex treatment, which is already implemented analogous to the palliative complex treatment. The patients receive targeted support from trained nursing staff, social services, physiotherapy, nutritional advice, hospital pharmacies and psycho-oncology. At the end of the oncological therapy and for the first aftercare after the end of therapy, the questionnaires on quality of life are filled out again in order to analyze changes. Initially, 20 patients are to be treated in a first phase (feasibility) in this concept of geriatric-oncological complex treatment in order to build up and expand the necessary structures for an interdisciplinary complex treatment and to set parameters for adherence to the therapy concept and maintaining quality of life and independence in the activities of the daily life for this collective of patients. As part of a follow-up study, vulnerable patients are then to be stratified and randomized using these parameters so that a more detailed analysis is possible.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 1, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Age from 75 years
• G8-Screening <15Pkt
• Potentially curative radiotherapy

Exclusion Criteria:

• no written informed consent
• life expectancy< 6 month

Related Conditions & MeSH terms

• Cancer

Locations

Country	Name	City	State
Germany	University Hospital of Heidelberg, Radiation Oncology	Heidelberg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiation associated changes in the independence in the activities of daily living	Changes in the Barthel Index	upt to 6 month after radiotherapy
Primary	Compliance to radiotherapy treatment	number of Events of premature termination of planned radiotherapy treatment	through treatment time of radiotherapy, an average of 6 weeks
Secondary	Therapy associated toxicity	Changes in toxicity assesment according to CTC	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	Sex	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	age	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	Barthel Index	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	Tumor entitiy	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	type of Radiation treatment	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	time of radiation treatment	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	rate of hospitalization Events	during radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	rate of hospitalization events	up to 6 month after radiotherapy
Secondary	Analysis of prognostic factors for radiotherapy Treatment success	required medications	up to 6 month after radiotherapy